Abbott’s nutritional products business has China in its rearview mirror as a pediatric market, progress on restoring infant formula manufacturing capacity, nearly 4% sales growth in its latest quarter and signs of tailwinds ahead.
Abbott Notes Formula For Revenue Tailwinds
US Infant Formula Sales Up 36% From Year-Ago Period When Recalls Began
Firm reports 3.8% Q1 growth in total nutritional sales to $1.97bn, driven by 19.9% growth in total US sales to $812m as formula and other pediatric product sales grew 36.1% to $465m and adult nutritional sales 3.9% to $353m.
